What is the generic name?

(DAUNORUBICIN AND CYTARABINE) LIPOSOME

What is the Trade Name for (DAUNORUBICIN AND CYTARABINE) LIPOSOME?

VYXEOS

What are the Indications for (DAUNORUBICIN AND CYTARABINE) LIPOSOME?

• 1 INDICATIONS AND USAGE VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. ( 1 )

References: https://open.fda.gov/